- Home
- SGHT vs TMCI Comparison
SGHT vs TMCI Comparison
Compare SGHT & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- TMCI
- Stock Information
- Founded
- SGHT 2011
- TMCI 2014
- Country
- SGHT United States
- TMCI United States
- Employees
- SGHT N/A
- TMCI N/A
- Industry
- SGHT Medical Specialities
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SGHT Health Care
- TMCI Health Care
- Exchange
- SGHT Nasdaq
- TMCI Nasdaq
- Market Cap
- SGHT 304.4M
- TMCI 329.0M
- IPO Year
- SGHT 2021
- TMCI 2021
- Fundamental
- Price
- SGHT $3.76
- TMCI $7.94
- Analyst Decision
- SGHT Buy
- TMCI Hold
- Analyst Count
- SGHT 6
- TMCI 6
- Target Price
- SGHT $6.80
- TMCI $7.40
- AVG Volume (30 Days)
- SGHT 264.4K
- TMCI 794.3K
- Earning Date
- SGHT 11-07-2024
- TMCI 11-05-2024
- Dividend Yield
- SGHT N/A
- TMCI N/A
- EPS Growth
- SGHT N/A
- TMCI N/A
- EPS
- SGHT N/A
- TMCI N/A
- Revenue
- SGHT $79,543,000.00
- TMCI $202,861,000.00
- Revenue This Year
- SGHT $3.06
- TMCI $13.15
- Revenue Next Year
- SGHT $10.33
- TMCI $8.36
- P/E Ratio
- SGHT N/A
- TMCI N/A
- Revenue Growth
- SGHT N/A
- TMCI 16.14
- 52 Week Low
- SGHT $2.58
- TMCI $3.92
- 52 Week High
- SGHT $8.45
- TMCI $15.98
- Technical
- Relative Strength Index (RSI)
- SGHT 31.07
- TMCI 69.09
- Support Level
- SGHT $3.65
- TMCI $7.21
- Resistance Level
- SGHT $3.85
- TMCI $8.37
- Average True Range (ATR)
- SGHT 0.29
- TMCI 0.49
- MACD
- SGHT -0.04
- TMCI 0.07
- Stochastic Oscillator
- SGHT 7.14
- TMCI 88.40
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.